Vysioneer

About Vysioneer

Vysioneer is an oncology AI company headquartered in Cambridge, MA, with a mission to use machine learning to bring therapies to cancer patients in need sooner. The company was founded on the belief that every tumor matters in the fight against cancer, addressing the critical challenge that 60% of cancer patients develop a mixture of shrinking, stable, and growing tumors—a phenomenon known as tumor heterogeneity that poses significant obstacles to personalized cancer medicine. Powered by their FDA-cleared, cloud-based AI platform, Vysioneer enhances drug efficacy assessment with lesion-level precision. Their AI-powered approach extracts all-lesion features beyond current response evaluation criteria and explores biomarkers that predict treatment outcomes. This enables pharmaceutical companies to conduct oncology trials with smaller sample sizes and confirm treatment outcomes sooner, while helping clinicians identify the right treatment for the right patient at the right time. Vysioneer's flagship product, VBrain, is an FDA-cleared AI-powered brain tumor auto-contouring solution that applies automated contouring to the three most common types of brain tumors: brain metastasis, meningioma, and acoustic neuroma. Clinical studies published in Neuro-Oncology demonstrated that clinicians assisted by VBrain showed a 12.2% increase in lesion detection, with fully automated contours generated in one minute compared to hours of manual work. The company serves both pharmaceutical/biotech companies for clinical trial optimization and healthcare providers for improved treatment planning and patient care.

Mission & Story

Clinical Focus

Medical conditions and clinical areas addressed by Vysioneer.

Who It Serves

Milestones & Awards

Key Partnerships